Stifel Nicolaus Upgrades Masimo (NASDAQ:MASI) to Buy

Stifel Nicolaus upgraded shares of Masimo (NASDAQ:MASI) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Marketbeat.com reports. Stifel Nicolaus currently has $170.00 target price on the medical equipment provider’s stock, up from their prior target price of $148.00.

MASI has been the subject of several other research reports. Piper Sandler boosted their target price on Masimo from $70.00 to $117.00 and gave the stock a neutral rating in a research note on Monday, February 26th. Jefferies Financial Group reissued a hold rating and issued a $121.00 price objective (up previously from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. BTIG Research boosted their target price on shares of Masimo from $145.00 to $166.00 and gave the stock a buy rating in a research note on Monday, March 25th. Wells Fargo & Company upgraded Masimo from an equal weight rating to an overweight rating and increased their price target for the company from $117.00 to $160.00 in a research note on Monday, March 25th. Finally, Needham & Company LLC downgraded Masimo from a buy rating to a hold rating in a report on Wednesday, January 3rd. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Masimo currently has a consensus rating of Hold and an average target price of $137.43.

Masimo Stock Performance

Shares of Masimo stock opened at $136.62 on Monday. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The company has a market cap of $7.23 billion, a PE ratio of 90.52 and a beta of 0.97. The company has a 50 day moving average of $135.65 and a 200-day moving average of $113.89. Masimo has a 1-year low of $75.22 and a 1-year high of $198.00.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. During the same period in the prior year, the company earned $1.32 earnings per share. The company’s quarterly revenue was down 11.0% on a year-over-year basis. As a group, equities research analysts forecast that Masimo will post 3.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Riverview Trust Co acquired a new stake in shares of Masimo in the first quarter valued at about $25,000. Massmutual Trust Co. FSB ADV raised its holdings in Masimo by 140.6% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the last quarter. Byrne Asset Management LLC acquired a new position in shares of Masimo in the 4th quarter worth approximately $28,000. DHJJ Financial Advisors Ltd. bought a new stake in shares of Masimo in the 3rd quarter valued at $32,000. Finally, NBC Securities Inc. acquired a new stake in shares of Masimo during the third quarter worth $34,000. 85.96% of the stock is owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.